Temporal patterns of late bowel and bladder radiotherapy toxicity in a randomised controlled trial assessing duration of neo-adjuvant hormones in prostate cancer

References

• Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:1124–9.
   PubMed Web of Science ®Google Scholar
• Christie D, Denham J, Steigler A, Lamb D, Turner S, Mameghan H, et al. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation. Radiother Oncol 2005;77:117–25.
   PubMed Web of Science ®Google Scholar
• Abdalla I, Ignacio L, Vaida F, Mei-Hsu, Awan A, Jani A, et al. Evolution of toxicity after conformal radiotherapy for prostate cancer. Prostate Cancer Prostatic Dis 2002;5: 296–303.
   PubMed Web of Science ®Google Scholar
• Karlsdottir A, Muren LP, Wentzel-Larsen T, Dahl O. Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity. Int J Radiat Oncol Biol Phys 2008;70:1478–86.
   PubMed Web of Science ®Google Scholar
• Huang EH, Pollack A, Levy L, Starkschall G, Dong L, Rosen I, et al. Late rectal toxicity: Dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2002;54:1314–21.
   PubMed Web of Science ®Google Scholar
• Armstrong JG, Gillham CM, Dunne MT, Armstrong JG, Gillham CM, Dunne MT, et al. A randomized trial (Irish Clinical Oncology Research Group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2011;81:35–45.
   PubMed Web of Science ®Google Scholar
• Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341–6.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–81.
   Web of Science ®Google Scholar
• Cox DR. Regression models and life tables. J Res Stats Soc 1972;34:187–220.
   Web of Science ®Google Scholar
• Fleming C, Kelly C, Thirion P, Fitzpatrick K, Armstrong J. A method for the prediction of late organ at risk toxicity after radiotherapy of the prostate using equivalent uniform dose. Int J Radiat Oncol Biol Phys 2011;80:608–13.
   PubMed Web of Science ®Google Scholar
• Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007;8:475–87.
   PubMed Web of Science ®Google Scholar
• Syndikus I, Morgan RC, Sydes MR, Graham JD, Dearnaley DP. Late gastrointestinal toxicity after dose- escalated conformal radiotherapy for early prostate cancer: Results from the UK Medical Research Council RT01 trial (ISRCTN47772397). Int J Radiat Oncol Biol Phys 2010;77:773–83.
   PubMed Web of Science ®Google Scholar
• Jereczek-Fossa BA, Zerini D, Fodor C, Santoro L, Serafini F, Cambria R, et al. Correlation between acute and late toxicity in 973 prostate cancer patients treated with three-dimensional conformal external beam radiotherapy. Int J Radiat Oncol Biol Phys 2010;78:26–34.
   PubMed Web of Science ®Google Scholar
• Peeters STH, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, et al. Dose response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter phase III randomized trial comparing 68 Gy with 78 Gy. J Clin Oncol 2006;24:1990–6.
   PubMed Web of Science ®Google Scholar
• Al-Mamgani A, Van Putten WLJ, Heemsbergen WD, Van Leenders GJLH, Slot A, Dielwart MFH, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;72:980–8.
   PubMed Web of Science ®Google Scholar
• Peeters STH, Heemsbergen WD, van Putten WLJ, Slot A, Tabak H, Mens JW, et al. Acute and late complications after radiotherapy for prostate cancer: Results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 2005;61:1019–34.
   PubMed Web of Science ®Google Scholar
• Nakamura RA, Monti CR, Castilho LN, Trevisan FA, Valim AC, Reinato JA. Prognostic factors for late urinary toxicity Grade 2–3 after conformal radiation therapy on patients with prostate cancer. Int Braz J Urol 2007;33:652–61.
   PubMedGoogle Scholar
• Scott CB, Pajak TF. LENT: A good beginning but.. Int J Radiat Oncol Biol Phys 1995;31:1347–8.
   PubMed Web of Science ®Google Scholar
• Gravis G, Marino P, Joly F, Oudard S, Priou F, Esterni B, et al. Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). Eur J Cancer 2014;50:953–62.
   PubMed Web of Science ®Google Scholar
• Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, et al. Comparison of conventional-dose versus high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA 2005;294:1233–9.
   PubMed Web of Science ®Google Scholar
• Capp A, Inostroza-Ponta M, Bill D, Moscato P, Lai C, Christie D, et al. Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial. Radiother Oncol 2009;90:400–7.
   PubMed Web of Science ®Google Scholar
• Odrazka K, Dolezel M, Vanasek J, Vaculikova M, Zouhar M, Sefrova J, et al. Time course of late rectal toxicity after radiation therapy for prostate cancer. Prostate Cancer Prostatic Dis 2010;13:138–42.
   PubMed Web of Science ®Google Scholar
• Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67–74.
   PubMed Web of Science ®Google Scholar
• Dearnaley DP, Hall E, Lawrence D, Huddart RA, Eeles R, Nutting CM, et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 2005; 92:488–98.
   PubMed Web of Science ®Google Scholar